ImmunityBio Faces Class Action Lawsuit Over Alleged Concealment of Drug Risks
In-Depth Analysis of ImmunityBio's Legal Troubles
The ongoing legal saga surrounding ImmunityBio, Inc., which recently began to unfold with a class action lawsuit, is drawing significant attention from investors and the medical community alike. The lawsuit, announced by SueWallSt, centers around serious allegations that the company's Executive Chairman concealed vital information regarding the potential risks associated with their primary drug, ANKTIVA. This situation has left shareholders, particularly those who purchased shares between January 19, 2026, and March 24, 2026, reeling from financial losses amounting to approximately $1.98 per share, representing a staggering 21% decline in stock value following an unfavorable FDA warning.
Background of the Allegations
The class action lawsuit argues that, during a notable podcast appearance on January 19, 2026, the Executive Chairman of ImmunityBio possessed key knowledge that was not disclosed to investors. Allegedly, this information would have tempered the optimistic portrayal of ANKTIVA as capable of treating various cancers, which contradicted its actual approval for use solely in specific bladder cancer cases—accounting for only 4.2% of new cancer diagnoses in 2025.
Moreover, the promotional communications from ImmunityBio, which suggested that ANKTIVA acted as a 'Cancer Therapeutic Vaccine,' misrepresented the drug's capabilities and safety, culminating in a subsequent FDA warning that declared the marketing claims as
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.